Revolution Medicines, Inc. Warrant (RVMD) Stock Forecast, Price Target & Predictions
RVMD Stock Forecast
Revolution Medicines, Inc. Warrant stock forecast is as follows: an average price target of $60.63 (represents a 6.24% upside from RVMD’s last price of $57.07) and a rating consensus of 'Buy', based on 15 wall street analysts offering a 1-year stock forecast.
RVMD Price Target
The average price target for Revolution Medicines, Inc. Warrant (RVMD) is $60.63 based on 1-year price targets from 15 Wall Street analysts in the past 3 months, with a price target range of $82.00 to $43.00. This represents a potential 6.24% upside from RVMD's last price of $57.07.
RVMD Analyst Ratings
According to 15 Wall Street analysts, Revolution Medicines, Inc. Warrant's rating consensus is 'Buy'. The analyst rating breakdown for RVMD stock is 1 'Strong Buy' (6.67%), 12 'Buy' (80.00%), 1 'Hold' (6.67%), 1 'Sell' (6.67%), and 0 'Strong Sell' (0.00%).
Revolution Medicines, Inc. Warrant Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 07, 2024 | Joseph Catanzaro | Piper Sandler | $70.00 | $56.09 | 24.80% | 22.66% |
| Nov 04, 2024 | Raghuram Selvaraju | H.C. Wainwright | $62.00 | $55.87 | 10.97% | 8.64% |
| Oct 28, 2024 | Michael Schmidt | Guggenheim | $82.00 | $46.96 | 74.62% | 43.68% |
| Oct 28, 2024 | Jay Olson | Oppenheimer | $60.00 | $46.83 | 28.12% | 5.13% |
| Oct 15, 2024 | Jay Olson | Oppenheimer | $55.00 | $49.22 | 11.74% | -3.63% |
| Sep 17, 2024 | Joseph Catanzaro | Piper Sandler | $57.00 | $44.24 | 28.84% | -0.12% |
| Aug 08, 2024 | Ami Fadia | Needham | $61.00 | $42.73 | 42.76% | 6.89% |
| Jul 15, 2024 | Robert Driscoll | Wedbush | $59.00 | $47.01 | 25.52% | 3.38% |
| Apr 19, 2024 | Ben Burnett | Stifel Nicolaus | $43.00 | $35.83 | 20.01% | -24.65% |
| Apr 12, 2024 | Ami Fadia | Needham | $46.00 | $37.41 | 22.96% | -19.40% |
The latest Revolution Medicines, Inc. Warrant stock forecast, released on Nov 07, 2024 by Joseph Catanzaro from Piper Sandler, set a price target of $70.00, which represents a 24.80% increase from the stock price at the time of the forecast ($56.09), and a 22.66% increase from RVMD last price ($57.07).
Revolution Medicines, Inc. Warrant Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 4 | 6 | 12 |
| Avg Price Target | $68.50 | $64.33 | $57.33 |
| Last Closing Price | $57.07 | $57.07 | $57.07 |
| Upside/Downside | 20.03% | 12.72% | 0.46% |
In the current month, the average price target of Revolution Medicines, Inc. Warrant stock is $68.50, according to 4 Wall Street analysts offering twelve months forecast. The average price target represents a 20.03% increase as opposed to Revolution Medicines, Inc. Warrant's last price of $57.07. This month's average price target is up 6.48% compared to last quarter, and up 19.48% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 28, 2024 | Guggenheim | Buy | Buy | Hold |
| Oct 28, 2024 | Needham | Buy | Buy | Hold |
| Oct 15, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Sep 27, 2024 | Barclays | Overweight | Overweight | Hold |
| Sep 17, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 08, 2024 | Needham | Buy | Buy | Hold |
| Jul 18, 2024 | Barclays | Overweight | Overweight | Hold |
| Jul 16, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Jul 16, 2024 | Keefe, Bruyette & Woods | Outperform | Outperform | Hold |
| Jul 16, 2024 | Piper Sandler | Overweight | Neutral | Downgrade |
Revolution Medicines, Inc. Warrant's last stock rating was published by Guggenheim on Oct 28, 2024. The company gave RVMD a "Buy" rating, the same as its previous rate.
Revolution Medicines, Inc. Warrant Financial Forecast
Revolution Medicines, Inc. Warrant Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $742.00K | - | $3.82M | $7.01M | $15.33M | $3.36M | $9.12M | $7.58M | $9.46M | $1.10M | $8.70M | $10.13M | $8.75M | $12.66M | $10.03M | $11.55M |
| Avg Forecast | $5.73M | $1.02M | - | - | $1.20M | $1.20M | $1.20M | $1.20M | $346.15K | $346.15K | $807.69K | $1.37M | $666.67K | $750.00K | $1.56M | $3.39M | $7.80M | $6.34M | $7.02M | $8.58M | $8.99M | $8.70M | $9.38M | $9.46M | $16.78M | $14.24M | $13.36M | $13.38M |
| High Forecast | $5.73M | $1.02M | - | - | $1.20M | $1.20M | $1.20M | $1.20M | $346.15K | $346.15K | $807.85K | $1.37M | $666.67K | $750.00K | $1.56M | $3.39M | $7.80M | $6.34M | $7.02M | $8.58M | $8.99M | $8.70M | $9.38M | $9.46M | $16.78M | $14.24M | $13.36M | $13.38M |
| Low Forecast | $5.73M | $1.02M | - | - | $1.20M | $1.20M | $1.20M | $1.20M | $346.15K | $346.15K | $807.54K | $1.37M | $666.67K | $750.00K | $1.56M | $3.39M | $7.80M | $6.34M | $7.02M | $8.58M | $8.99M | $8.70M | $9.38M | $9.46M | $16.78M | $14.24M | $13.36M | $13.38M |
| # Analysts | 3 | 3 | - | - | 4 | 5 | 2 | 2 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.11% | - | 2.45% | 2.07% | 1.96% | 0.53% | 1.30% | 0.88% | 1.05% | 0.13% | 0.93% | 1.07% | 0.52% | 0.89% | 0.75% | 0.86% |
Revolution Medicines, Inc. Warrant's average Quarter revenue forecast for Mar 24 based on 3 analysts is $1.37M, with a low forecast of $1.37M, and a high forecast of $1.37M. RVMD's average Quarter revenue forecast represents a 85.00% increase compared to the company's last Quarter revenue of $742.00K (Dec 23).
Revolution Medicines, Inc. Warrant EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | - | - | 4 | 5 | 2 | 2 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-157.27M | $-123.25M | $-108.80M | $-75.16M | $-56.63M | $-71.19M | $-58.89M | $-55.36M | $-50.61M | $-51.19M | $-42.46M | $-35.49M | $-32.13M | $-25.57M | $-25.58M | $-18.63M |
| Avg Forecast | $-5.69M | $-1.02M | - | - | $-1.19M | $-1.19M | $-1.19M | $-1.19M | $-344.14K | $-344.14K | $-803.00K | $-65.75M | $-662.80K | $-745.65K | $-1.55M | $-59.77M | $-42.15M | $-6.30M | $-6.98M | $-54.34M | $-8.94M | $-8.65M | $-9.33M | $-34.80M | $-16.68M | $-14.16M | $-13.28M | $-16.56M |
| High Forecast | $-5.69M | $-1.02M | - | - | $-1.19M | $-1.19M | $-1.19M | $-1.19M | $-344.14K | $-344.14K | $-802.85K | $-52.60M | $-662.80K | $-745.65K | $-1.55M | $-47.82M | $-33.72M | $-6.30M | $-6.98M | $-43.47M | $-8.94M | $-8.65M | $-9.33M | $-27.84M | $-16.68M | $-14.16M | $-13.28M | $-13.25M |
| Low Forecast | $-5.69M | $-1.02M | - | - | $-1.19M | $-1.19M | $-1.19M | $-1.19M | $-344.14K | $-344.14K | $-803.16K | $-78.90M | $-662.80K | $-745.65K | $-1.55M | $-71.73M | $-50.58M | $-6.30M | $-6.98M | $-65.21M | $-8.94M | $-8.65M | $-9.33M | $-41.76M | $-16.68M | $-14.16M | $-13.28M | $-19.87M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 237.28% | 165.29% | 70.04% | 1.26% | 1.34% | 11.30% | 8.44% | 1.02% | 5.66% | 5.92% | 4.55% | 1.02% | 1.93% | 1.81% | 1.93% | 1.13% |
undefined analysts predict RVMD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Revolution Medicines, Inc. Warrant's previous annual EBITDA (undefined) of $NaN.
Revolution Medicines, Inc. Warrant Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | - | - | 4 | 5 | 2 | 2 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-171.13M | $-108.43M | $-98.30M | $-58.51M | $-56.51M | $-73.33M | $-60.35M | $-57.34M | $-52.68M | $-52.94M | $-44.30M | $-37.18M | $-34.20M | $-27.22M | $-27.21M | $-19.52M |
| Avg Forecast | $-182.28M | $-178.99M | $-178.12M | $-182.98M | $-180.19M | $-175.37M | $-171.48M | $-166.10M | $-167.44M | $-149.03M | $-129.25M | $-68.85M | $-142.29M | $-168.62M | $-137.29M | $-62.59M | $-43.87M | $-139.02M | $-140.37M | $-56.90M | $-105.45M | $-103.33M | $-92.48M | $-36.46M | $-63.41M | $-64.74M | $-59.78M | $-17.35M |
| High Forecast | $-182.28M | $-178.99M | $-178.12M | $-182.98M | $-180.19M | $-175.37M | $-171.48M | $-158.04M | $-159.23M | $-149.03M | $-129.25M | $-55.08M | $-115.82M | $-168.62M | $-137.29M | $-50.07M | $-35.09M | $-139.02M | $-140.37M | $-45.52M | $-105.45M | $-103.33M | $-92.48M | $-29.17M | $-63.41M | $-64.74M | $-59.78M | $-13.88M |
| Low Forecast | $-182.28M | $-178.99M | $-178.12M | $-182.98M | $-180.19M | $-175.37M | $-171.48M | $-180.62M | $-188.78M | $-149.03M | $-129.25M | $-82.62M | $-182.00M | $-168.62M | $-137.29M | $-75.11M | $-52.64M | $-139.02M | $-140.37M | $-68.28M | $-105.45M | $-103.33M | $-92.48M | $-43.75M | $-63.41M | $-64.74M | $-59.78M | $-20.82M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.20% | 0.64% | 0.72% | 0.93% | 1.29% | 0.53% | 0.43% | 1.01% | 0.50% | 0.51% | 0.48% | 1.02% | 0.54% | 0.42% | 0.46% | 1.13% |
Revolution Medicines, Inc. Warrant's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RVMD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Revolution Medicines, Inc. Warrant SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | - | - | 4 | 5 | 2 | 2 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $32.24M | $15.51M | $14.64M | $13.22M | $10.91M | $10.43M | $10.20M | $9.04M | $8.69M | $7.79M | $7.30M | $6.67M | $5.83M | $5.34M | $5.09M | $5.17M |
| Avg Forecast | $10.83M | $1.93M | - | - | $2.27M | $2.27M | $2.27M | $2.27M | $654.92K | $654.92K | $1.53M | $2.60M | $1.26M | $1.42M | $2.96M | $6.41M | $7.24M | $11.64M | $12.89M | $15.77M | $16.51M | $15.98M | $17.23M | $6.54M | $30.82M | $26.16M | $24.54M | $4.60M |
| High Forecast | $10.83M | $1.93M | - | - | $2.27M | $2.27M | $2.27M | $2.27M | $654.92K | $654.92K | $1.53M | $2.60M | $1.26M | $1.42M | $2.96M | $6.41M | $8.69M | $11.64M | $12.89M | $15.77M | $16.51M | $15.98M | $17.23M | $7.85M | $30.82M | $26.16M | $24.54M | $5.52M |
| Low Forecast | $10.83M | $1.93M | - | - | $2.27M | $2.27M | $2.27M | $2.27M | $654.92K | $654.92K | $1.53M | $2.60M | $1.26M | $1.42M | $2.96M | $6.41M | $5.79M | $11.64M | $12.89M | $15.77M | $16.51M | $15.98M | $17.23M | $5.23M | $30.82M | $26.16M | $24.54M | $3.68M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 25.56% | 10.93% | 4.95% | 2.06% | 1.51% | 0.90% | 0.79% | 0.57% | 0.53% | 0.49% | 0.42% | 1.02% | 0.19% | 0.20% | 0.21% | 1.13% |
Revolution Medicines, Inc. Warrant's average Quarter SG&A projection for Mar 24 is $2.60M, based on 3 Wall Street analysts, with a range of $2.60M to $2.60M. The forecast indicates a -91.95% fall compared to RVMD last annual SG&A of $32.24M (Dec 23).
Revolution Medicines, Inc. Warrant EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | - | - | 4 | 5 | 2 | 2 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $-0.00 | $-0.62 | $-0.63 | $-0.87 | $-0.81 | $-0.77 | $-0.71 | $-0.72 | $-0.60 | $-0.53 | $-0.52 | $-0.42 | $-0.46 | $-0.74 |
| Avg Forecast | $-1.09 | $-1.07 | $-1.07 | $-1.10 | $-1.08 | $-1.05 | $-1.03 | $-1.00 | $-1.00 | $-0.89 | $-0.77 | $-0.75 | $-0.85 | $-1.01 | $-0.82 | $-0.80 | $-0.82 | $-0.84 | $-0.85 | $-0.78 | $-0.64 | $-0.63 | $-0.56 | $-0.52 | $-0.38 | $-0.39 | $-0.36 | $-0.33 |
| High Forecast | $-1.09 | $-1.07 | $-1.07 | $-1.10 | $-1.08 | $-1.05 | $-1.03 | $-0.95 | $-0.95 | $-0.89 | $-0.77 | $-0.75 | $-0.69 | $-1.01 | $-0.82 | $-0.80 | $-0.82 | $-0.84 | $-0.85 | $-0.78 | $-0.64 | $-0.63 | $-0.56 | $-0.52 | $-0.38 | $-0.39 | $-0.36 | $-0.33 |
| Low Forecast | $-1.09 | $-1.07 | $-1.07 | $-1.10 | $-1.08 | $-1.05 | $-1.03 | $-1.08 | $-1.13 | $-0.89 | $-0.77 | $-0.75 | $-1.09 | $-1.01 | $-0.82 | $-0.80 | $-0.82 | $-0.84 | $-0.85 | $-0.78 | $-0.64 | $-0.63 | $-0.56 | $-0.52 | $-0.38 | $-0.39 | $-0.36 | $-0.33 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.77% | 0.77% | 1.03% | 0.95% | 0.99% | 1.11% | 1.15% | 1.07% | 1.01% | 1.35% | 1.07% | 1.27% | 2.22% |
According to undefined Wall Street analysts, Revolution Medicines, Inc. Warrant's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RVMD previous annual EPS of $NaN (undefined).
Revolution Medicines, Inc. Warrant Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| PASG | Passage Bio | $0.51 | $6.00 | 1076.47% | Buy |
| BDTX | Black Diamond Therapeutics | $2.43 | $14.75 | 507.00% | Buy |
| CCCC | C4 Therapeutics | $4.05 | $13.50 | 233.33% | Buy |
| SANA | Sana Bio | $2.53 | $8.00 | 216.21% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| STOK | Stoke Therapeutics | $11.31 | $30.60 | 170.56% | Buy |
| AKRO | Akero Therapeutics | $30.64 | $46.00 | 50.13% | Buy |
| NRIX | Nurix Therapeutics | $22.64 | $32.20 | 42.23% | Buy |
| RNA | Avidity Biosciences | $43.65 | $54.50 | 24.86% | Buy |
| PTGX | Protagonist Therapeutics | $40.65 | $50.00 | 23.00% | Buy |
| KYMR | Kymera Therapeutics | $44.05 | $51.50 | 16.91% | Buy |
| BPMC | Blueprint Medicines | $94.81 | $109.71 | 15.72% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $57.07 | $60.63 | 6.24% | Buy |
| AGIO | Agios Pharmaceuticals | $54.62 | $48.00 | -12.12% | Buy |